A New Hope: FDA Clears Trial for Novel Drug Targeting Debilitating Cancer-Related Wasting

MONTVALE, NJ – May 27, 2026 – For the millions of cancer patients who suffer from a devastating and often fatal wasting syndrome, a new glimmer of hope has emerged. EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application, allowing the company to proceed with a Phase 2a clinical trial for its lead drug candidate, EOM613, in patients with cancer cachexia.

The decision marks a critical milestone in the fight against a condition that currently has no FDA-approved treatments, profoundly impacting patient quality of life and survival.

The Invisible Burden of Cancer Cachexia

Cancer cachexia is more than just weight loss. It is a complex and debilitating metabolic syndrome characterized by a severe, involuntary loss of muscle and fat. This "wasting syndrome" affects an estimated 50% to 80% of patients with advanced cancers and is a direct cause of death in up to one-third of all cancer fatalities. Patients experience extreme weakness, fatigue, and anorexia, which can render them too frail to tolerate life-extending treatments like chemotherapy.

"EOM has designed a Phase 2a clinical trial for the treatment of cancer cachexia patients who currently have no approved therapies," stated Shalom Z. Hirschman, MD, Chief Medical Officer of EOM, in the company's press release. The urgency is palpable within the oncology community, where clinicians have long struggled with limited palliative options that only manage symptoms without addressing the underlying inflammatory process driving the condition.

This process is largely driven by an uncontrolled release of pro-inflammatory cytokines, such as Interleukin-6 and TNF-alpha, which leads to muscle breakdown and disrupts the brain's appetite signals. Unlike simple malnutrition, cachexia cannot be reversed by nutritional support alone, creating a desperate need for a targeted pharmacological intervention.

A Broad-Spectrum Attack on Inflammation

EOM613 is not another single-target drug. It is a peptide nucleic acid-based agent designed as a broad-spectrum immune regulator. Its proposed "dynamic dual action" mechanism aims to restore balance to the immune system by modulating both pro- and anti-inflammatory cytokines, rather than simply blocking one pathway. This novel approach could be key to taming the complex "cytokine storm" that fuels cachexia.

"In previous clinical trials in cachectic AIDS patients and COVID-19 patients, EOM613 treatment was well-tolerated, even in extremely sick patients," Dr. Hirschman noted, highlighting the drug's promising safety profile. Indeed, EOM613 has a history of investigation across several inflammatory conditions. Early open-label trials in rheumatoid arthritis and AIDS cachexia, as well as a Health Canada-approved study in cancer patients, showed beneficial effects on weight stabilization and functional status.

This background provides a foundation of evidence suggesting EOM613 could be a versatile tool against diseases driven by immune dysregulation.

The Path Forward and a Competitive Field

The newly approved open-label Phase 2a trial is set to begin in the third quarter of 2026. Led by Principal Investigator Dr. Azriel Hirschfeld at Hirschfeld Oncology in Brooklyn, NY, the study will enroll approximately 20 patients with Stage 4 cancer. Over three months, researchers will assess the effect of daily subcutaneous injections of EOM613 on weight, lean body mass, appetite, and quality of life. A key secondary goal is to see if functional improvements allow more patients to become eligible for another round of chemotherapy, a potentially game-changing outcome.

While EOM's news is promising, the company is entering a competitive, albeit unproven, therapeutic landscape. Several other companies are racing to develop the first approved cachexia treatment. Pfizer's late-stage candidate, Ponsegromab, targets a specific cytokine called GDF-15, while others like Actimed Therapeutics and Endevica Bio are advancing drugs with different mechanisms. The market remains a high-risk, high-reward arena, but for a micro-cap biotech like EOM, a successful trial could be transformative.

Beyond Cancer: A Platform for Inflammatory Disease

EOM is also looking to leverage EOM613's unique mechanism beyond oncology. The company announced plans for an additional exploratory trial in patients with moderate to severe Crohn's disease, another condition driven by a cytokine-imbalance. That trial, expected to start in the fourth quarter of 2026, will be led by Dr. Arkady Broder of the St. Peter’s Healthcare System in New Jersey.

With the global market for inflammatory bowel disease (IBD) therapies projected to exceed $25 billion annually, success in this area would represent a massive expansion of EOM613's potential. This dual-pronged strategy—targeting the urgent unmet need in cancer cachexia while simultaneously exploring a major chronic disease market—highlights the company's ambition to establish its lead asset as a true platform therapy for a range of complex inflammatory conditions.